Circulating miRNAs for glioblastoma monitoring: from biofluid to clinical decision
Arthur Leclerc, Evelyne Emery, Guénaëlle Levallet · 2026
Read Circulating miRNAs for glioblastoma monitoring: from biofluid to clinical decision by Arthur Leclerc, Evelyne Emery, Guénaëlle Levallet (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13476693.txt.
Description
Arthur Leclerc, Evelyne Emery, and Guénaëlle Levallet review in 2026 blood microRNAs as trackers for glioblastoma, the most lethal common brain tumor. Standard scans struggle to tell true growth from treatment effects. Studies across plasma, serum, and spinal fluid were gathered for diagnosis, outlook, and drug response uses. Panels of small RNAs beat single markers in most reports.
Cancer-driving small RNAs ran high in patients, while guard types ran low. Some levels tracked survival, treatment reply, and even temozolomide drug resistance. Two serum markers followed scan tumor size and split true growth from false alarms. Assay standards and large checks still block clinic use.
Catalog record
| CREATOR | Arthur Leclerc, Evelyne Emery, Guénaëlle Levallet |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 76 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |